About 16% of breast cancers fall into a clinically aggressive category designated "triple negative" (TNBC) due to a lack of ERBB2, estrogen receptor and progesterone receptor expression 1-3 . The mutational spectrum of TNBC has been characterized as part of The Cancer Genome Atlas (TCGA) 4 ; however, snapshots of primary tumors cannot reveal the mechanisms by which TNBCs progress and spread. To address this limitation we initiated the Intensive Trial of OMics in Cancer (ITOMIC)-001, in which patients with metastatic TNBC undergo multiple biopsies over space and time 5 . Whole exome sequencing (WES) of 67 samples from 11 patients identified 426 genes containing multiple distinct single nucleotide variants (SNVs) within the same sample, instances we term "Multiple SNVs affecting the Same Gene and Sample" (MSSGS). We find that >90% of MSSGS result from cis-compound mutations (in which both SNVs affect the same allele), that MSSGS comprised of SNVs affecting adjacent nucleotides arise from single mutational events, and that most other MSSGS result from the sequential acquisition of SNVs. Some MSSGS drive cancer progression, as exemplified by a TNBC driven by FGFR2(S252W;Y375C) . MSSGS are more prevalent in TNBC than other breast cancer subtypes and occur at higher-than-expected frequencies across TNBC samples within TCGA. MSSGS may denote genes that play as yet unrecognized roles in cancer progression.
3 subsequent therapies. Additional samples are accessed as archival tissues, as leftovers following clinically indicated procedures, and from tissues taken at autopsy. Samples are selected for sequencing based on specimen size and tumor content ( Fig. 1a) . Results from 11 of the first 12 subjects are presented here because low tumor purities in Subject 08 precluded analysis. We performed WES of germline DNA and 67 tumor samples (Extended Data Table 1), including transiently cultured cells derived from a malignant pleural effusion in Subject 01 and two highly enriched samples of circulating tumor cells (CTCs) obtained following leukapheresis in Subject 02 5 . Whole genome sequencing (WGS) was also performed in 39 samples. The number of assessed samples per patient ranged from 2 to 16 (median 7), and the number of assessed time points ranged from 1 to 6 (median 3) ( Table 1) .
Our analysis focused on somatic single nucleotide variants (SNVs), which comprise the majority of mutations in breast cancer 4, 6, 7 . WES identified a total of 8449 SNVs, of which 7067 occurred within 5136 protein coding genes, including 43 breast cancer driver genes (0.84%) 7 (data not shown). Across all 67 samples, 1403 genes were affected by >1 SNV. Remarkably, 426 genes were found to contain >1 SNV within the same tumor sample (Extended Data Table 1), and we designated these instances Multiple SNVs affecting the Same Gene and Sample (MSSGS) (Fig. 1b) .
MSSGS were observed in 65 of 67 samples, with a median of 8 and a range of 0 to 133 MSSGS per sample (Extended Data Table 1 ). The distribution of median transcript sizes was no larger for MSSGS than for genes affected by single SNVs 8 (Extended Data Fig. 1) . Concomitant Methods) . While somatic variants are unevenly distributed across cancer genomes 8 , we found similar mutation densities in regions surrounding MSSGS compared to isolated SNVs ( Fig. 2a) with the exception of an MSSGS involving MUC4, which fell within a region of kataegis 9 (Fig. 2b) .
MSSGS can arise when two or more SNVs affect: i) the same gene in different tumor cells, ii) different alleles in the same cell, or iii) the same allele in the same cell (ciscompound mutation) ( Fig. 1c) . To assess the frequency with which SNVs contributing to MSSGS co-localize to form a cis-compound mutation we cloned and sequenced tumor DNA from eight patients, revealing a very high frequency of cis-compound mutations (12 of 13 evaluable MSSGS -92%) ( Table 2) . Haplotype phasing 10 of 407 MSSGS similarly indicated that >90% were attributable to cis-compound mutations (Extended Data Fig. 4c) , and ponatinib treatment in the patient produced a regression of breast cancer infiltrates in the skin (Fig. 4d) . Possibly indicative of a growth advantage conferred by other MSSGS are results from Table 2 , which show that for MSSGS involving ABHD16Ac, TMPRSS13 and ROBO4, sequences bearing the entire cis-compound mutation are more abundant than sequences containing only one of the component SNVs.
We reasoned that if cis-compound mutations can confer a selective advantage in TNBC, MSSGS might be more prevalent than would be predicted from a random co-localization of SNVs. To address this question we evaluated 106 TNBC samples from the TCGA.
Fig. 5s
shows the number of SNVs contributing to MSSGS against the total SNV count for each of 106 TNBC samples from TCGA 4 . We also plotted a theoretical curve under the null hypothesis that MSSGS arise from the random co-localization of SNVs (see
Supplementary Methods
). The assumptions inherent in generating this theoretical curve exert a greater impact at high SNV counts; therefore, in Fig. 5b we exclude the 5 samples containing >600 SNVs, and focus on the remaining 101 samples carrying fewer than 200 SNVs. As expected, the number of SNVs contributing to MSSGS increases in accordance with the total number of SNVs. However, Fig. 5b also shows that the number of observed SNVs contributing to MSSGS tends to exceed levels predicted by the theoretical curve. These results indicate that for many samples, the number of SNVs contributing to MSSGS is higher than predicted had they arisen independently. To further examine this phenomenon, we performed a permutation test for each of the 106 patients to test the null hypothesis that SNVs co-localize to form MSSGS randomly (details are provided in Methods). With the 106 resulting p-values, we accept six patients when we use the Benjamini-Hochberg (BH) procedure 16 to control the false discovery rate at 0.05 ( Fig. 5b) .
Finally, we assessed the frequency of MSSGS in 993 breast cancer samples from TCGA. While there were no significant differences in the mean or median numbers of MSSGS per sample (data not shown), nor in the fraction of MSSGS per SNV, a higher percentage of TNBCs contained at least 1 MSSGS (74.5%) compared to HER2+ breast cancers (61.5%), or ER+ breast cancers (49.7%) ( Fig. 5c-f ).
Evidence presented here supports the involvement of MSSGS in tumor growth based on our findings that: i) The large majority of MSSGS are attributable to cis-compound mutations; ii) FGFR2(S252W;Y375C) has unambiguous functional significance; iii) sequences bearing the entire cis-compound mutation are frequently more abundant than sequences bearing only one of the component SNVs; and iv) MSSGS are detected at significantly higher frequencies than would be predicted from the random co-localization of SNVs in subsets of patients with TNBC. MSSGS lack many features of conventional driver mutations because they are not widely detected across tumors from different individuals, are typically present at sub-clonal levels, and are frequently not associated with cancer initiation but rather cancer progression. Some of the MSSGS described here are unlikely drivers of cancer progression, exemplified by MUC4, which resides in a region of increased mutation density (Extended Data Fig. 2 ).
Epistastic interactions between missense mutations can enable proteins to evolve new
conformations and functions 17, 18 . Cis-compound mutations associated with gain-offunction 19, 20 and loss-of-function 21 
underpin inherited disorders such as Multiple
Endocrine Neoplasia Type 2B 19 , long QT syndrome 21 , and familial Alzheimer's Disease 20 . Cis-compound mutations have also been described in cancer [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , provide an important mechanism of resistance to BCR-ABL targeted tyrosine kinase inhibitors [29] [30] [31] , and can promote the re-acquisition of sensitivity in previously crizotinib resistant, ALKrearranged lung cancer 32 
Biopsies
Biopsies of metastases involving lymph nodes, subcutaneous tissues, and liver were performed under ultrasound guidance using an 18 gauge BioPince Full-Core Biopsy instrument. Up to 5 disease sites were biopsied in a single setting, and multiple biopsies were performed per disease site. Bone marrow biopsies were taken from the iliac crest using a Jamshidi T-Handle needle. Skin biopsies were performed using 3 -4 mm punch biopsy instrument. In Subject 2 circulating tumor cells were collected by leukapheresis. All biopsies were performed using local anesthesia and most were performed using conscious sedation. Biopsy specimens were processed in accordance with a standardized set of operating procedures and subjects were contacted one day and one week following the procedure to assess for complications.
Rapid On-Site Evaluation
Core biopsy samples of metastases involving lymph nodes, soft tissues, or liver were immediately photographed and divided orthogonally. One half was formalin fixed (for formalin fixation and paraffin embedding [FFPE] ) and the other half was gently pressed against an RNAse treated slide to generate a touch prep, then immediately snap frozen. Cytological evaluation of the touch prep was performed by a pathologist in real time and, if necessary, additional biopsies were procured to optimize sample size and tumor content. The time interval between sample acquisition and the completion of processing (known as the cold ischemia time) was recorded and was, except for the bone marrow biopsies and leukaphereses, less than 5 minutes in all cases ( Table 2) . 
Selection of Biopsy Specimens for Further Testing

Residual Clinical Materials
When feasible, leftover blood samples and pleural fluid specimens were processed and stored for analysis. The estimated time between sample collection and processing was recorded.
Autopsy Samples
At the time of this submission, Subjects 
Whole Genome Sequencing
Confirmation of a subset of MSSGs was done by NantOmics (Culver City, CA), which performed whole genome sequencing (WGS) in 39 of the 67 samples described here, using the same DNA that had been tested by WES. WGS Sequencing was performed on the Illumina HiSeq X sequencing platform using libraries prepared via the KAPA Hyper prep kit. Tumor genomes were sequenced to an average depth of 60x, and Normal genomes were sequenced to an average depth of 30x. Mutations were identified using the CLIA-validated NantOmics Contraster pipeline as previously described 35 .
Germline Genome
Germline variant detection is performed to identify genes associated with inherited cancer syndromes, such as mutations involving BRCA1 or BRCA2.
Data Management
Clinical data are entered into REDCap, a web--based application for Electronic Data 
Comparing sizes of genes affected by MSSGS versus isolated SNVs
To assess whether the formation of MSSGS is related to gene size, we compared the distributions of the median transcript sizes between genes affected by MSSGs versus genes affected by isolated SNVs. We performed the Wilcoxon rank-sum test to compare the means of the two distributions and found no significant difference (Extended Data Fig. 1 ). Gene transcript sizes were obtained from Biomart (Ensembl).
Haplotype phasing of SNVs associated with MSSGS
To assess the orientation of neighbouring SNVs within MSSGs, we used
ReadBackedPhasing from Genome Analysis Toolkit version 3.3.0. Phasing information with at least 20.0 quality score was used to assess whether a pair of SNVs are cis or trans.
Evaluating the local mutation rates in regions surrounding MSSGS vs isolated
SNVs.
To assess whether the formation of MSSGS is driven by elevated local mutation rates, we compared local mutation rates surrounding MSSGS with mutation rates genome wide. In order to calculate the local mutation rate for each MSSGS, we counted the number of SNVs identified by WGS in a 1 megabase window centered on each MSSGS (obtained by subtracting transcriptional stop site by the transcriptional start site, using
RefSeq transcripts as a reference). We then calculated the local mutational rate across the genome by windowing each sample into 1MB windows and counting the number of SNVs. A plot of the local mutation rates surrounding MSSGS is depicted by the red circles shown in Figure 2a . Additionally, the distance between each neighboring SNV identified in the WGS samples was calculated to identify regions of kataegis 9 , which we defined as at least 10 SNVs in a 100 kilobase window. Only one MSSGS, involving MUC4, landed in such a region (Figure 2b) .
The theoretical distribution of SNVs contributing to MSSGS
Suppose that a patient carries m SNVs in the tumor cells. Let N (N=17,672) be the total number of genes subject to possible mutation in TNBC, and W be a vector of length N.
We assume that each gene can be mutated with a probability proportional to W, and W = 0.8W 1 + 0.2W2, where W 1 is the normalized gene mutation frequency in TNBC samples in TCGA and W 2 is the normalized gene mutation frequency in non-TNBC BC samples in TCGA. We include the term 0.2W 2 because there are only 106 TNBC samples (in which 7,933 genes are mutated), and we want to use W 2 to mimic the unseen genes (which can be potentially mutated in TNBC). In each round of permutation, we randomly assign each of the m SNVs to one of the 17,672 genes with a probability proportional to W, and then count SNVs in MSSGS. We repeat this procedure 10,000 times, and each time we obtain a count of the number of SNVs contributing to MSSGS. We then use the median of these 10,000 counts as the expected number of SNVs contributing to MSSGS. The entire simulation procedure is repeated for m from 1 up to 1500, where 1500 is the maximal number of SNVs observed in the TCGA cohort.
To assign a patient-specific P-value, we repeat the above simulation procedure using the observed value of m. We then compare the observed count of SNVs contributing to MSSGS with the 10,000 count values from the simulation. We define the P-value as (t + 1)/10001, where t is the number of times that the observed count of SNVs contributing to MSSGS is less than or equal to the count from simulations.
High Throughput Drug Screen
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